Literature DB >> 34102141

How We Prevent and Treat Delirium in the ICU.

Jessica A Palakshappa1, Catherine L Hough2.   

Abstract

Delirium is a serious and complex problem facing critically ill patients, their families, and the health care system. When delirium develops, it is associated with prolonged hospital stays, increased costs, and long-term cognitive impairment in many patients. This article uses a clinical case to discuss our approach to delirium prevention and treatment in the ICU. We believe that an effective strategy to combat delirium requires implementation and adherence to a pain and sedation protocol as part of bundled care, use of a validated tool to detect delirium when present, and a focus on nonpharmacologic care strategies, including reorientation, early mobility, and incorporating family into care when possible. At present, the evidence does not support the routine administration of medications to prevent or treat delirium. A pharmacologic approach may be needed for agitated delirium, and we discuss our evaluation of the evidence for and against particular medications. Although delirium can be a distressing problem, there is evidence that it can be addressed through careful attention to prevention, detection, and minimizing the long-term impact on patients and their families.
Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  critical care; delirium; implementation

Mesh:

Substances:

Year:  2021        PMID: 34102141      PMCID: PMC8727852          DOI: 10.1016/j.chest.2021.06.002

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   10.262


  55 in total

1.  Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.

Authors:  John W Devlin; Yoanna Skrobik; Céline Gélinas; Dale M Needham; Arjen J C Slooter; Pratik P Pandharipande; Paula L Watson; Gerald L Weinhouse; Mark E Nunnally; Bram Rochwerg; Michele C Balas; Mark van den Boogaard; Karen J Bosma; Nathaniel E Brummel; Gerald Chanques; Linda Denehy; Xavier Drouot; Gilles L Fraser; Jocelyn E Harris; Aaron M Joffe; Michelle E Kho; John P Kress; Julie A Lanphere; Sharon McKinley; Karin J Neufeld; Margaret A Pisani; Jean-Francois Payen; Brenda T Pun; Kathleen A Puntillo; Richard R Riker; Bryce R H Robinson; Yahya Shehabi; Paul M Szumita; Chris Winkelman; John E Centofanti; Carrie Price; Sina Nikayin; Cheryl J Misak; Pamela D Flood; Ken Kiedrowski; Waleed Alhazzani
Journal:  Crit Care Med       Date:  2018-09       Impact factor: 7.598

2.  The Hospital Elder Life Program: a model of care to prevent cognitive and functional decline in older hospitalized patients. Hospital Elder Life Program.

Authors:  S K Inouye; S T Bogardus; D I Baker; L Leo-Summers; L M Cooney
Journal:  J Am Geriatr Soc       Date:  2000-12       Impact factor: 5.562

3.  Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit.

Authors:  E Wesley Ely; Ayumi Shintani; Brenda Truman; Theodore Speroff; Sharon M Gordon; Frank E Harrell; Sharon K Inouye; Gordon R Bernard; Robert S Dittus
Journal:  JAMA       Date:  2004-04-14       Impact factor: 56.272

4.  Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients With Agitated Delirium: A Randomized Clinical Trial.

Authors:  Michael C Reade; Glenn M Eastwood; Rinaldo Bellomo; Michael Bailey; Andrew Bersten; Benjamin Cheung; Andrew Davies; Anthony Delaney; Angaj Ghosh; Frank van Haren; Nerina Harley; David Knight; Shay McGuiness; John Mulder; Steve O'Donoghue; Nicholas Simpson; Paul Young
Journal:  JAMA       Date:  2016-04-12       Impact factor: 56.272

5.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  BMJ       Date:  2009-07-21

Review 6.  Clinical benefits of dexmedetomidine versus propofol in adult intensive care unit patients: a meta-analysis of randomized clinical trials.

Authors:  Zhi-Qiu Xia; Shu-Qin Chen; Xi Yao; Chuan-Bo Xie; Shi-Hong Wen; Ke-Xuan Liu
Journal:  J Surg Res       Date:  2013-07-24       Impact factor: 2.192

Review 7.  Dexmedetomidine vs propofol sedation reduces delirium in patients after cardiac surgery: A meta-analysis with trial sequential analysis of randomized controlled trials.

Authors:  Xu Liu; Guohao Xie; Kai Zhang; Shengwen Song; Fang Song; Yue Jin; Xiangming Fang
Journal:  J Crit Care       Date:  2016-11-11       Impact factor: 3.425

8.  Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.

Authors:  Timothy D Girard; Matthew C Exline; Shannon S Carson; Catherine L Hough; Peter Rock; Michelle N Gong; Ivor S Douglas; Atul Malhotra; Robert L Owens; Daniel J Feinstein; Babar Khan; Margaret A Pisani; Robert C Hyzy; Gregory A Schmidt; William D Schweickert; R Duncan Hite; David L Bowton; Andrew L Masica; Jennifer L Thompson; Rameela Chandrasekhar; Brenda T Pun; Cayce Strength; Leanne M Boehm; James C Jackson; Pratik P Pandharipande; Nathan E Brummel; Christopher G Hughes; Mayur B Patel; Joanna L Stollings; Gordon R Bernard; Robert S Dittus; E Wesley Ely
Journal:  N Engl J Med       Date:  2018-10-22       Impact factor: 91.245

9.  Occurrence of delirium is severely underestimated in the ICU during daily care.

Authors:  Peter E Spronk; Bea Riekerk; José Hofhuis; Johannes H Rommes
Journal:  Intensive Care Med       Date:  2009-04-07       Impact factor: 17.440

10.  The effectiveness of non-pharmacological interventions in reducing the incidence and duration of delirium in critically ill patients: a systematic review and meta-analysis.

Authors:  Leona Bannon; Jennifer McGaughey; Rejina Verghis; Mike Clarke; Daniel F McAuley; Bronagh Blackwood
Journal:  Intensive Care Med       Date:  2018-11-30       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.